曹流，中山大学医学院副教授，硕士生导师。2010-2019年在武汉大学生命科学学院就读，获得学士和博士学位；2019-2023年在中山大学医学院完成博士后和特聘副研究员工作；2023年转聘为中山大学副教授。目前主要从事冠状病毒感染机制和抗病毒药物研究。
研究方向1：通过多组学手段探究病毒宿主间相互作用，以及挖掘抗病毒基因。研究方向2： 设计针对冠状病毒的小分子/多肽药物，并通过多种病毒和动物模型筛选验证。作为主要完成人的“SHEN26”新冠病毒口服小分子药物已经完成临床二期试验。近5年内以第一作者/共通讯作者共发表SCI学术论文13篇，包括Science Translational Medicine、Cell Research、Plos Pathogens、Signal Transduction and Targeted Therapy、mBio、Journal of Medicinal Chemistry等。单篇研究性论文最高引用589余次。主持了国家自然科学基金青年项目，国家自然科学基金原创探索项目，中国博士后面上项目等项目。欢迎对科研感兴趣的学生报考！联系方式：caoliu@mail.sysu.edu.cn
发表论文（第一作者/通讯作者）：
1. Liu Cao#, Yingjun Li#，*, Sidi Yang#, Guanguan Li#, Qifan Zhou#, Jing Sun#, Tiefeng Xu, Yang Yang, Ruyan Liao, Yongxia Shi, Yujian Yang, Tiaozhen Zhu, Siyao Huang, Yanxi Ji, Feng Cong, Yinzhu Luo, Yujun Zhu, Hemi Luan, Huan Zhang, Jingdiao Chen, Xue Liu, Renru Luo, Lihong Liu, Ping Wang, Yang Yu, Fan Xing, Bixia Ke, Huanying Zheng, Xiaoling Deng, Wenyong Zhang, Chuwen Lin, Mang Shi, Chun-Mei Li, Yu Zhang, Lu Zhang, Jun Dai, Hongzhou Lu, Jincun Zhao*, Xumu Zhang*, Deyin Guo*. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Science Translational Medicine. 2022/9, 14(661): eabm7621. (IF: 19.319)
2. Liu Cao, Yanxi Ji, Lanyi Zeng, Qianyun Liu, Zhen Zhang, Shuting Guo, Xiaolong Guo, Yongjia Tong, Xiaolu Zhao, Chun-Mei Li, Yu Chen*, Deyin Guo*. P200 family protein IFI204 negatively regulates type I interferon responses by targeting IRF7 in nucleus. Plos Pathogens. 2019/10, 15(10): e1008079. (IF: 7.464)
3. Junyu Wu#, Chunyan Wu#, Fan Xing#, Liu Cao#, Weijie Zeng, Liping Guo, Ping Li, Yongheng Zhong, Hualian Jiang, Manhui Luo, Guang Shi, Lang Bu, Yanxi Ji, Panpan Hou, Hong Peng, Junjiu Huang, Chunmei Li, Deyin Guo*. Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells. Cell Research. 2021/6, 31(9):998-1010. (IF: 46.351)
4. Qifan Zhou#, Sidi Yang#, Liu Cao#, Yang Yang#, Tiefeng Xu#, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduction and Targeted Therapy. 2023/1, 8(1):27. (IF: 38.104)
5. Ruangang Pan#, Eveline Kindler#, Liu Cao#, Yu Zhou, Zhen Zhang, Qianyun Liu, Nadine Ebert, Roland Züst, Ying Sun, Alexander E. Gorbalenya, Stanley Perlman*, Volker Thiel*, Yu Chen*, Deyin Guo*. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition. mBio. 2022/1, 13(1): e0366221. (IF: 7.786)
6. Yingjun Li#, Liu Cao#, Ge Li, Feng Cong, Yunfeng Li, Jing Sun, Yinzhu Luo, Guijiang Chen, Guanguan Li, Ping Wang, Fan Xing, Yanxi Ji, Jincun Zhao, Yu Zhang*, Deyin Guo*, Xumu Zhang*. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. Journal of Medicinal Chemistry. 2022/2, 65(4): 2785-2793. (IF: 8.039)
7. Liu Cao#, Tiefeng Xu#, Xue Liu#, Yanxi Ji, Siyao Huang, Hong Peng, Chunmei Li, Deyin Guo*. The Impact of Accumulated Mutations in SARS-CoV-2 Variants on the qPCR Detection Efficiency. Frontiers in Cellular and Infection Microbiology. 2022/1, 12:823306. (IF: 6.073)
8. Weijie Zeng#, Fan Xing#, Yanxi Ji, Sidi Yang, Tiefeng Xu, Siyao Huang, Chunmei Li, Junyu Wu*, Liu Cao*, Deyin Guo*. Evidence of infection of human embryonic stem cells by SARS-CoV-2. Frontiers in Cellular and Infection Microbiology. 2022/6, 12: 911313. (IF: 6.073)
9. Yong Xiong#, Yuan Liu#, Liu Cao#, Dehe Wang#, Ming Guo, Ao Jiang, Dong Guo, Wenjia Hu, Jiayi Yang, Zhidong Tang, Honglong Wu, Yongquan Lin, Meiyuan Zhang, Qi Zhang, Mang Shi, Yingle Liu, Yu Zhou*, Ke Lan*, Yu Chen*. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & Infections. 2020/3, 9 (1): 761-770. (IF: 19.568，被引用589次)
10. Yujian Yang#, Liu Cao#, Ming Yan, Jun Zhou, Sidi Yang, Tiefeng Xu, Siyao Huang, Kun Li, Qifan ZHou, Guanguan Li, Yujun Zhu, Cong Feng, Hongming Zhang, Deyin Guo, Yingjun Li,Xumu Zhang. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2. Antiviral Research. 2023/5, 213:105586. (IF: 10.103)
11. Sidi Yang#, Liu Cao#, Wenting Xu, Tiefeng Xu, Birong Zheng, Yanxi Ji, Siyao Huang, Lihong Liu, Jie Du, Hong Peng, Huan Zhang, Jingdiao Chen, Bixia Ke, Huanying Zheng, Xiaoling Deng, Chunmei Li, Deyin Guo*. Comparison of model-specific histopathology in mouse models of COVID-19. Journal of Medical Virology. 2022/8, 94(8):3605-3612. (IF: 20.693)
12. Geng Chen#, Yang Yang#, Qi-Jia Wu#, Liu Cao#, Wen Ruan, Changwei Shao, Li Jiang, Peng Tang, Suping Ma, Ao Jiang, Zhen Wang, Kai Wu, Qiangfeng Cliff Zhang, Xiang-Dong Fu, Yu Zhou*. ILF3 represses repeat-derived microRNAs targeting RIG-I mediated type I interferon response. Journal of Molecular Biology. 2022/4, 434(7):167469. (IF: 6.151)
13. Yanxi Ji#, Liu Cao#, Lanyi Zeng, Zhen Zhang, Qiaoqiao Xiao, Penglin Guan, Shiyou Chen, Yu Chen, Min Wang*, Deyin Guo*. The N-terminal ubiquitin-associated domain of Cezanne is crucial for its function to suppress NF-κB pathway. Journal of Cellular Biochemistry. 2018/2, 119(2): 1979-1991. (IF: 4.481)
